Table 2.

Adverse events related to 3,4-DAP treatment in Lambert–Eaton myasthenic syndrome

Adverse event	Patients (n = 51)	%
SAE
Seizure	1	2
AE
Paresthesias	22	43
Fatigue	6	12
Epigastric distress	6	12
Sleeplessness	5	10
Shortness of breath	1	2
Increased tearing	1	2
Urinary urge	1	2
Pain in arm of IV administration	8/9	89

Note: Data from references22,35–37 as summarized in Wirtz et al.⁴³

Abbreviations: 3,4-DAP, 3,4-diaminopyridine; AE, adverse events; SAE, serious adverse events; IV, intravenous.